A group of 17 leading European ophthalmologists and researchers have gathered together under Eurocondor, the European Consortium for the Early Treatment of Diabetic Retinopathy, with the aim of testing a new eye drop treatment that could prevent the development of diabetic retinopathy.
Diabetic retinopathy (DR) –the general term for all eye complications caused by diabetes- is the leading cause of blindness among working-age individuals in developed countries. Current treatments of DR are only indicated in advanced stages of the disease and are intrusive, costly and associated with significant side-effects. For this reason, new non-intrusive pharmacological treatments for the early stages of the disease are needed. Such new treatment could open a new field of research, reduce the socio-economic burden of treating DR, and ultimately improve the lives of people living with diabetes.
The EUROCONDOR project held its 6th and final General Assembly on 22-23 June 2016 at Citylabs facilities in Manchester, U.K.